This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	β -Amyloid ($A\beta$); acetylcholinesterase (AChE); butyrylcholinesterase (BChE)	<p>Studies in cell culture suggest that compounds having both antioxidant and anticholinesterase activity could help treat AD. <i>In vitro</i>, the compounds were low micromolar inhibitors of AChE and BChE, and they decreased AD-related $A\beta_{1-42}$ aggregation by up to 45% compared with that in controls. Planned studies include testing the compounds in animal models of AD and neuroprotection.</p> <p>Compounds in Phase III testing for AD include the $A\beta$-targeting mAbs bapineuzumab from Elan Corp. plc and Wyeth and LY2062430 from Eli Lilly and Co.</p> <p>SciBX 2(41); doi:10.1038/scibx.2009.1536 Published online Oct. 22, 2009</p>	Patented by University of Bologna; available for licensing	<p>Bolognesi, M.L. <i>et al. J. Med. Chem.</i>; published online Oct. 8, 2009; doi:10.1021/jm901123n Contact: Maria Laura Bolognesi, University of Bologna, Bologna, Italy e-mail: marialaura.bolognesi@unibo.it</p>